DE69526728D1 - VERWENDUNG VON IL-12 UND IL-12 ANTAGONISTEN zur Herstellung eines Arzneimittels FÜR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN - Google Patents

VERWENDUNG VON IL-12 UND IL-12 ANTAGONISTEN zur Herstellung eines Arzneimittels FÜR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN

Info

Publication number
DE69526728D1
DE69526728D1 DE69526728T DE69526728T DE69526728D1 DE 69526728 D1 DE69526728 D1 DE 69526728D1 DE 69526728 T DE69526728 T DE 69526728T DE 69526728 T DE69526728 T DE 69526728T DE 69526728 D1 DE69526728 D1 DE 69526728D1
Authority
DE
Germany
Prior art keywords
autoimmune
treatment
antagonists
medicine
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69526728T
Other languages
English (en)
Other versions
DE69526728T3 (de
DE69526728T2 (de
Inventor
John P Leonard
Samuel Goldman
O'hara, Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69526728(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE69526728D1 publication Critical patent/DE69526728D1/de
Application granted granted Critical
Publication of DE69526728T2 publication Critical patent/DE69526728T2/de
Publication of DE69526728T3 publication Critical patent/DE69526728T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DE69526728T 1994-03-14 1995-03-07 Verwendung von IL-12 und IL-12 Antagonisten zur Herstellung eines Arzneimittels für Behandlung von Autoimmunkrankheiten Expired - Lifetime DE69526728T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14
PCT/US1995/002550 WO1995024918A1 (en) 1994-03-14 1995-03-07 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases
US212629 2002-08-05

Publications (3)

Publication Number Publication Date
DE69526728D1 true DE69526728D1 (de) 2002-06-20
DE69526728T2 DE69526728T2 (de) 2002-11-21
DE69526728T3 DE69526728T3 (de) 2007-01-04

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526728T Expired - Lifetime DE69526728T3 (de) 1994-03-14 1995-03-07 Verwendung von IL-12 und IL-12 Antagonisten zur Herstellung eines Arzneimittels für Behandlung von Autoimmunkrankheiten

Country Status (14)

Country Link
US (1) US6338848B1 (de)
EP (4) EP1179348A3 (de)
JP (1) JP3798426B2 (de)
AT (1) ATE217533T1 (de)
AU (1) AU689236B2 (de)
CA (1) CA2185565C (de)
DE (1) DE69526728T3 (de)
DK (1) DK0750509T4 (de)
ES (1) ES2173953T5 (de)
IL (1) IL112677A (de)
PT (1) PT750509E (de)
TW (1) TW400233B (de)
WO (1) WO1995024918A1 (de)
ZA (1) ZA95960B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
EP0936923B1 (de) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
WO1999037682A2 (en) * 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
ATE305506T1 (de) * 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
CA2362381C (en) 1999-02-10 2009-12-22 Welfide Corporation Amide compounds and medicinal use thereof
JP4841038B2 (ja) * 1999-03-25 2011-12-21 アボット ゲーエムベーハー ウント カンパニー カーゲー ヒトｉｌ−１２に結合するヒト抗体およびその産生法
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2006069036A2 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
CA2575675A1 (en) 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
JP2012504555A (ja) * 2008-09-30 2012-02-23 ベイラー リサーチ インスティテュート 自己免疫疾患を治療するためにｂヘルパーｔ細胞を減少させる方法
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201127400A (en) 2009-09-14 2011-08-16 Abbott Lab Methods for treating psoriasis
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8962317B2 (en) 2010-09-28 2015-02-24 Neumedicines, Inc. Uses of IL-12 and the IL-12 receptor positive cell in tissue repair and regeneration
PE20141060A1 (es) 2010-12-21 2014-09-26 Abbvie Inc Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
US20140314710A1 (en) * 2011-05-19 2014-10-23 Rush University Medical Center IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment
EP2736530B1 (de) * 2011-07-27 2018-06-06 Neumedicines, Inc Verwendung von il-12 zur erzeugung von endogenem erythropoetin
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
KR20190107184A (ko) 2012-11-01 2019-09-18 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
JP7359845B2 (ja) 2018-09-24 2023-10-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ATE366311T1 (de) * 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (de) † 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Interleukin-12 Rezeptoren und Antikörper
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
WO1999037682A2 (en) * 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及系统、光网络单元

Also Published As

Publication number Publication date
CA2185565A1 (en) 1995-09-21
EP0750509B2 (de) 2006-06-14
ATE217533T1 (de) 2002-06-15
EP2311484A1 (de) 2011-04-20
ZA95960B (en) 1995-10-10
EP0750509B1 (de) 2002-05-15
EP1179348A2 (de) 2002-02-13
DK0750509T4 (da) 2006-10-16
TW400233B (en) 2000-08-01
CA2185565C (en) 2009-02-03
AU689236B2 (en) 1998-03-26
DE69526728T3 (de) 2007-01-04
PT750509E (pt) 2002-08-30
JP3798426B2 (ja) 2006-07-19
WO1995024918A1 (en) 1995-09-21
EP1179348A3 (de) 2003-12-03
US6338848B1 (en) 2002-01-15
EP0750509A1 (de) 1997-01-02
AU1974995A (en) 1995-10-03
IL112677A (en) 2000-01-31
DE69526728T2 (de) 2002-11-21
ES2173953T5 (es) 2007-03-01
DK0750509T3 (da) 2002-07-08
ES2173953T3 (es) 2002-11-01
EP2201959A3 (de) 2011-03-16
IL112677A0 (en) 1995-05-26
JPH09510444A (ja) 1997-10-21
EP2201959A2 (de) 2010-06-30

Similar Documents

Publication Publication Date Title
DE69526728D1 (de) VERWENDUNG VON IL-12 UND IL-12 ANTAGONISTEN zur Herstellung eines Arzneimittels FÜR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN
Saxne et al. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis
Colley et al. Five cases demonstrating the distinctive behavioural features of chromosome deletion 17 (p 11.2 p 11.2)(Smith‐Magenis syndrome)
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE264860T1 (de) Pyrazolotriazine als crf antagonisten
Moss et al. Family visiting with institutionalized mentally impaired aged
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
KR890011589A (ko) 벤즈아미드의 용도
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69029884D1 (de) 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten
Stone Sleep and aging in animals: Relationships with circadian rhythms and memory
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE121945T1 (de) Verwendung von gamma-interferon zur herstellung eines medikaments für die behandlung von steroid- abhängigem asthma.
Kirk et al. A brief inservice training strategy to increase levels of empathy of psychiatric nursing personnel.
Zachariae et al. The Electroencephalogram in Patients with Dupuytren's Contracture: Electroencephalographic and Clinical Neurological Study of 78 Dupuytren Patients
Furuzawa et al. Diurnal variation of heart rate, locomotor activity, and body temperature in interleukin-1α/β doubly deficient mice
ATE157546T1 (de) Verwendung von anabolika zur herstellung eines arzneimittels zur behandlung von seniler dementia und der alzheimerschen krankheit
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
Lolas et al. Affective content of speech as a predictor of psychotherapy outcome
ATE128188T1 (de) Menschliches gamma-interferon, verfahren zu seiner herstellung und seine verwendung.
Donohue Relationship between substance use and characteristics of persons with spinal cord injuries.
Götestam A three‐dimensional treatment programme for chronic pain
McDERMOTT JR Psychotherapy with children and adolescents: Introduction
Faircloth A comparison of the reinforcing effects of self and imposed electrical brain stimulation
Klein Regarding neuropsychological findings in silicone breast-implant complainants: A comment on Youngjohn, Spector, and Mapou

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN